Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3237 ↗At a glance
Journal article in Clinical Pharmacology & Therapeutics, 2024. Written by Junghyun Cho and 8 co-authors. Institution: Division of Nephrology, Soonchunhyang University Seoul Hospital, Seoul, Korea. Major MEDLINE topics: Benzhydryl Compounds, Albuminuria, Glucosides, Biomarkers. Cited 11 times so far (Crossref); 36 references. Funded by: Ministry of Science and Technology Information and Communication, Medical Research Center, Soonchunhyang University Research Fund.
Abstract (original language)
The beneficial effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD) with low albuminuria levels have not been established. This study aimed to compare the effects of dapagliflozin on kidney injury biomarkers in patients with CKD stratified by albuminuria level. We prospectively enrolled healthy volunteers (HVs; n = 20) and patients with CKD ( n = 54) with and without diabetes mellitus. Patients with CKD were divided into two age‐matched and sex‐matched subgroups according to urinary albumin–creatinine ratio (uACR) levels (
Subjects
MeSH terms (MEDLINE)
Substances
Authors and institutions
- Division of Nephrology, Soonchunhyang University Seoul Hospital, Seoul, Korea.
- Department of Urology, Soonchunhyang University Seoul Hospital, Seoul, Korea.
- Hyonam Kidney Laboratory, Soonchunhyang University Seoul Hospital, Seoul, Korea.
ORCID profiles: Junghyun Cho, Seung Whan Doo, Nayoung Song, Minsul Lee, Haekyung Lee, Hyongnae Kim, Jin Seok Jeon, Hyunjin Noh, Soon Hyo Kwon
Funding
- Ministry of Science and Technology Information and Communication
- Medical Research Center
- Soonchunhyang University Research Fund
Cite
APA
Cho, J., Doo, S. W., Song, N., Lee, M., Lee, H., Kim, H., Jeon, J. S., Noh, H., & Kwon, S. H. (2024). Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3237
Vancouver
Cho J, Doo SW, Song N, Lee M, Lee H, Kim H, et al. Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3237
BibTeX
@article{Cho2024,
author = {Cho, Junghyun and Doo, Seung Whan and Song, Nayoung and Lee, Minsul and Lee, Haekyung and Kim, Hyongnae and Jeon, Jin Seok and Noh, Hyunjin and Kwon, Soon Hyo},
title = {Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3237}
}
EUVIMED